Dhillon et al. measured IL-33 levels in patients with myocardial infarction and found that elevated IL-33 was associated with increased mortality in ST-elevation myocardial infarction (STEMI) [24], but was not related to adverse events in non–ST-elevation myocardial infarction (NSTEMI) patients [25]. The gene discussed is IL33; the disease is ST Elevation Myocardial Infarction.